The biotech industry in New Jersey has grown despite a sluggish economy and interruptions in global credit markets, according to a report from trade group BioNJ and accounting company Ernst & Young. The sector's continued development, however, could be hampered by dwindling early-stage financing, high operating expenses and other problems, the report said.

Full Story:
NJBIZ (New Jersey)

Related Summaries